Cover Image
市場調查報告書

關節黏性補給療法 - 全球市場分析與預測

MediPoint: Viscosupplementation - Middle East and Africa Analysis and Market Forecasts

出版商 GlobalData 商品編碼 339690
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
關節黏性補給療法 - 全球市場分析與預測 MediPoint: Viscosupplementation - Middle East and Africa Analysis and Market Forecasts
出版日期: 2017年04月01日 內容資訊: 英文 27 Pages
簡介

骨關節炎(OA)持續成長為一個公共健康的重擔,也是世界各國肌肉骨骼障礙的一個常見原因。過去十年間,在OA症狀管理中使用玻尿酸(HA)補充增加關節內黏性的療法,已經成為一種普遍被用來取代關節置換手術的選項。今後為了因應醫藥費改革的必要性,需要更進一步推廣關節黏性補給療法。只是專家學者仍抱有疑慮的現況下,關節黏性補給療法可能無法獲得保險理賠。此外由於市場競爭非常嚴峻,各企業為了凸顯產品差異而正積極進行開發活動。以地區分類來看,美國及亞洲市場的成長率最為顯著。

本報告針對全球關節黏性補給療法市場進行分析,調查且考察了療法與相關疾病的概要、基本市場構造、已上市/試驗中的主要產品概略、全球及各地區主要國家的市場趨勢與未來預測、主要企業檔案等內容,提供如後。

第1章 目次

第2章 前言

第3章 療法概要

  • 治療範例
    • 物理治療
    • 藥物治療
    • 玻尿酸關節黏性補給療法
    • 外科手術

第4章 產業概要

  • 程序趨勢
    • 概要
    • 美國
    • 歐盟五國
    • 亞洲
    • 南美
  • 進入市場的途徑
  • 醫藥費給付
  • 企業合併與收購(M&A)及主要合夥(共5件)

第5章 市場促進因素、市場機會、障礙

  • 促進因素:OA的盛行率上升
  • 促進因素:OA的複合療法範例
  • 促進因素:關節黏性補給療法推遲了膝關節的完全置換
  • 促進因素:NSAID、類固醇、麻醉藥的副作用
  • 促進因素:向消費者直接販售
  • 市場機會:適應症的增加
  • 市場機會:新世代波尿酸衍生物
  • 市場機會:關節鏡手術後的使用增加
  • 市場機會:自費市場
  • 市場機會:新興國家市場
  • 障礙:不利的給付方案
  • 障礙:價格崩壞
  • 障礙:有成本效益的藥物療法
  • 障礙:PRP注射的人氣上升是否會影響關節黏性補給療法市場?
  • 障礙:新興國家的高成本意識患者

第6章 未滿足需求

  • 缺乏對膝關節OA關節黏性補給療法的一致意見
  • 證明其他關節的關節黏性補給療法臨床效力的證據不足
  • 對基礎科學認知的進展
  • 超音波引導式注射

第7章 競爭評估

  • 主要關節黏性補給療法產品
    • Adant
    • Arthrum
    • Curavisc
    • Durolane
    • Euflexxa
    • Fermathron
    • Gel-One
    • GoOn
    • Hyalgan
    • Hyalubrix 及 HyalOne
    • Jonexa
    • NeoVisc
    • Orthovisc 及 Monovisc
    • Ostenil
    • Recosyn
    • RenehaVis
    • Supartz/ARTZ
    • Suplasyn
    • Suvenyl
    • Synocrom
    • Synolis V-A
    • Synovial
    • Synvisc 及 Synvisc-1
  • 其他關節黏性補給療法產品

第8章 開發中產品

  • 概要
  • Gel-Syn (IBSA Institut Biochimique S.A.)
  • Cingal (Anika Therapeutics)
  • Hydros-TA (Carbylan Therapeutics)
  • Synvisc-1 (Sanofi) 的額外適應症
  • Hymovis (Fidia Farmaceutici S.p.A.)
  • HA-NSAID複合物(Seikagaku Corporation)
  • Supartz/ARTZ(Seikagaku Corporation)的額外適應症
  • Clodronate-HA複合物 (Abiogen Pharma)

第9章 現在及未來主要企業

  • 企業策略趨勢
  • 主要製造商
    • Anika Therapeutics
    • 中外製藥
    • Ferring Pharmaceuticals
    • Fidia Farmaceutici S.p.A.
    • Meda AB
    • Sanofi
    • Seikagaku Corporation
  • 主要行銷夥伴
    • Bioventus
    • DePuy Synthes
    • Zimmer-Biomet

第10章 市場展望

  • 各國市佔率分析
    • 美國市場
    • 歐盟5國市場
    • 亞洲市場
    • 巴西市場
  • 依市場分類
    • 單次注射
    • 3次注射
    • 5次注射
  • 依地域分類
    • 概要
    • 美國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
    • 日本
    • 巴西
    • 中國
    • 印度

第11章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Middle East and Africa viscosupplementation market was estimated at $26.3M in 2016 across the five markets (Egypt, Israel, Saudi Arabia, South Africa, and United Arab Emirates [UAE]). By the end of the forecast period in 2023, it is estimated that the market will grow to approximately $37.0M at a Compound Annual Growth Rate (CAGR) of 5.0%.

Osteoarthritis (OA) constitutes a growing public health burden, and is the most common cause of musculoskeletal disability around the world. Resulting from a complex interaction of biomechanical, biochemical, and genetic factors, OA develops slowly and is characterized by the degradation of the affected joint's cartilage and bone hypertrophy. The disability is accompanied by joint pain, stiffness, and loss of range of motion. Initially treated with various therapies including physical therapy and nonsteroidal anti-inflammatory drugs (NSAIDs), advanced cases of OA have traditionally been treated surgically. However, intra-articular viscosupplementation with hyaluronic acid (HA), a high-molecular-weight glycosaminoglycan, has become an increasingly accepted therapeutic alternative to knee replacement surgery in the symptomatic management of OA over the past decade.

South Africa represented the largest portion of the market in 2016, holding almost 65.0% of the regional revenue, and is expected to maintain this dominance through the forecast period. South Africa is also expected to be the fastest-growing market through 2023, at a CAGR of 5.2%, while the slowest growth will be observed in the UAE at a CAGR of 3.8%.

Key drivers of the viscosupplementation market in the forecast period are -

  • The rising prevalence of osteoarthritis (OA) due to increasing aging and obese populations.
  • The evolving multimodal treatment paradigm for OA.
  • Patients seeking to delay knee replacement surgery in an effort to maintain an active lifestyle.

The market for viscosupplementation is highly fragmented, with key players varying by region and country. Unlike most orthopedic device markets, the market for viscosupplementation is largely populated by pharmaceutical companies. Although many companies maintain a direct presence in the markets they sell to, some have coordinated marketing and distribution partnerships with major orthopedic players in an effort to leverage geographical experience and existing relationships with orthopedic surgeons.

The report "MediPoint: Viscosupplementation - Middle East and Africa Analysis and Market Forecasts" focuses on the market outlook for viscosupplementation products in the Middle East and Africa (Egypt, Israel, Saudi Arabia, South Africa, and United Arab Emirates). The analysis discusses the major drivers and barriers of adoption, and provides an in-depth understanding of the future outlook for this market by segment and geography.

Companies mentioned in this report: Anika Therapeutics, Ferring Pharmaceuticals, Fidia Farmaceutici, Sanofi, Seikagaku Corporation.

Scope

  • Overview of recent key industry events and analysis of their market impact.
  • Annualized total market revenue by type of device, procedure trends, and market outlooks by segment and by country through 2023.
  • Key topics covered include strategic competitor assessment, market characterization, and implications of the emerging technologies in the market.
  • Pipeline analysis: Comprehensive data split across different stages of development, including a discussion of emerging trends and devices in development.
  • Analysis of the current and future market competition in the Middle East and Africa viscosupplementation market. Insightful review of the key industry drivers, barriers, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of marketed products and technologies.
  • Develop business strategies by understanding the trends shaping and driving the viscosupplementation market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the viscosupplementation market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track device sales in country-specific viscosupplementation markets from 2014-2023.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 About the Authors 2

  • 1.1 Analysts 2
    • 1.1.1 Jennifer Ryan, Orthopedic Analyst, Medical Devices 2
    • 1.1.2 Linda Tian, Managing Analyst, Medical Devices 2
    • 1.1.3 Global Head of Medical Devices 2

2 Table of Contents 3

  • 2.1 List of Tables 5
  • 2.2 List of Figures 5

3 Executive Summary 6

  • 3.1 Overview 6
  • 3.2 Market Dynamics 7
  • 3.3 Key Players in the Viscosupplementation Market 8
  • 3.4 Viscosupplementation Market Future Outlook 8

4 Introduction 9

  • 4.1 Catalyst 9
  • 4.2 Related Reports 9
  • 4.3 Upcoming Related Reports 10

5 Market Outlook 11

  • 5.1 Procedure Trends 11
  • 5.2 Pricing Trends 11
  • 5.3 Revenue Trends 11
  • 5.4 Company Share Analysis 12

6 Market Insights 13

  • 6.1 Middle East and Africa 13
    • 6.1.1 Israel 13
    • 6.1.2 South Africa 13
    • 6.1.3 Egypt, Saudi Arabia, and UAE 13

7 Competitive Assessment 15

  • 7.1 Overview 15
  • 7.2 Anika Therapeutics 15
    • 7.2.1 Overview 15
    • 7.2.2 Portfolio Assessment 16
    • 7.2.3 Competitive Positioning 16
  • 7.3 Ferring Pharmaceuticals 16
    • 7.3.1 Overview 16
    • 7.3.2 Portfolio Assessment 17
    • 7.3.3 Competitive Positioning 17
  • 7.4 Fidia Farmaceutici 17
    • 7.4.1 Overview 17
    • 7.4.2 Portfolio Assessment 17
    • 7.4.3 Competitive Positioning 18
  • 7.5 Sanofi 18
    • 7.5.1 Overview 18
    • 7.5.2 Portfolio Assessment 19
    • 7.5.3 Competitive Positioning 19
  • 7.6 Other Players 20

8 Appendix 22

  • 8.1 Bibliography 22
  • 8.2 Abbreviations 22
  • 8.3 Methodology 23
    • 8.3.1 Overview 23
    • 8.3.2 Coverage 23
    • 8.3.3 Secondary Research 23
    • 8.3.4 Forecasting Methodology 24
    • 8.3.5 Primary Research Summary 25
  • 8.4 About MediPoint 26
  • 8.5 About GlobalData 26
  • 8.6 Contact Us 26
  • 8.7 Disclaimer 27

List of Tables

List of Tables

  • Table 1: Key Metrics in the Middle East and Africa Viscosupplementation Market 6
  • Table 2: Middle East and Africa Viscosupplementation Volume Forecast, 2014-2023 11
  • Table 3: Middle East and Africa Viscosupplementation Average Selling Price Forecast ($), 2014-2023 11
  • Table 4: Middle East and Africa Viscosupplementation Market Revenue Forecast ($M), 2014-2023 12
  • Table 5: Middle East and Africa Viscosupplementation Company Share Analysis, 2016 12
  • Table 6: Anika Therapeutics - Key Marketed Products Assessment 16
  • Table 7: Ferring Pharmaceuticals - Key Marketed Products Assessment 17
  • Table 8: Fidia Farmaceutici - Key Marketed Products Assessment 17
  • Table 9: Fidia Farmaceutici - Key Clinical Trials 18
  • Table 10: Sanofi - Key Marketed Products Assessment 19
  • Table 11: Summary of Other Players in the Viscosupplementation Market, 2017 20

List of Figures

List of Figures

  • Figure 1: Viscosupplementation Sales for the Middle East and Africa, by Country, 2016 and 2023 7
Back to Top